{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:53:06Z","timestamp":1777942386712,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","award":["SHSESP-007"],"award-info":[{"award-number":["SHSESP-007"]}],"id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling of the dose-toxicity relationship have been developed. The main ones are: the continual reassessment method (CRM), the escalation with overdose control (EWOC) method and, for late-onset and cumulative toxicities, the time-to-event continual reassessment method (TITE-CRM) and the time-to-event escalation with overdose control (TITE-EWOC) methods. The objective of this work was to perform a user-friendly R package that combines the latter model-guided adaptive designs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GUIP1 is an R Graphical User Interface for dose escalation strategies in Phase 1 cancer clinical trials. It implements the CRM (based on Bayesian or maximum likelihood estimation), EWOC and TITE-CRM methods using the dfcrm and bcrm R packages, while the TITE-EWOC method has been specifically developed. The program is built using the TCL\/TK programming language, which can be compiled via R software libraries (tcltk, tkrplot, tcltk2). GUIP1 offers the possibility of simulating and\/or conducting and managing phase I clinical trials in real-time using file management options with automatic backup of study and\/or simulation results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>GUIP1 is implemented using the software R, which is widely used by statisticians in oncology. This package simplifies the use of the main model-based dose escalation methods and is designed to be fairly simple for beginners in R. Furthermore, it offers multiple possibilities such as a full traceability of the study. By including multiple innovative adaptive methods in a free and user-friendly program, we hope that GUIP1 will promote and facilitate their use in designing future phase I cancer clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12911-020-01149-3","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T11:02:54Z","timestamp":1592996574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials"],"prefix":"10.1186","volume":"20","author":[{"given":"D.","family":"Dinart","sequence":"first","affiliation":[]},{"given":"J.","family":"Fraisse","sequence":"additional","affiliation":[]},{"given":"D.","family":"Tosi","sequence":"additional","affiliation":[]},{"given":"A.","family":"Mauguen","sequence":"additional","affiliation":[]},{"given":"C.","family":"Touraine","sequence":"additional","affiliation":[]},{"given":"S.","family":"Gourgou","sequence":"additional","affiliation":[]},{"given":"M. C.","family":"Le Deley","sequence":"additional","affiliation":[]},{"given":"C.","family":"Bellera","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-3684","authenticated-orcid":false,"given":"C.","family":"Mollevi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"issue":"3","key":"1149_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45(3):925\u201337.","journal-title":"Biometrics"},{"issue":"12","key":"1149_CR2","doi-asserted-by":"publisher","first-page":"e51039","DOI":"10.1371\/journal.pone.0051039","volume":"7","author":"C Le Tourneau","year":"2012","unstructured":"Le Tourneau C, Gan HK, Razak ARA, Paoletti X. Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents. PLoS One. 2012;7(12):e51039 Stemmer SM, editor.","journal-title":"PLoS One"},{"issue":"3","key":"1149_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0167-9473(98)00095-4","volume":"30","author":"E Reiner","year":"1999","unstructured":"Reiner E, Paoletti X, O\u2019Quigley J. Operating characteristics of the standard phase I clinical trial design. Comput Stat Data Anal. 1999;30(3):303\u201315.","journal-title":"Comput Stat Data Anal"},{"issue":"31","key":"1149_CR4","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1200\/JCO.2007.12.1012","volume":"25","author":"A Rogatko","year":"2007","unstructured":"Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. J Clin Oncol. 2007;25(31):4982\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1149_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2531628","volume":"46","author":"J O\u2019Quigley","year":"1990","unstructured":"O\u2019Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46(1):33\u201348.","journal-title":"Biometrics"},{"issue":"2","key":"1149_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2307\/2532905","volume":"52","author":"J O\u2019Quigley","year":"1996","unstructured":"O\u2019Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996;52(2):673\u201384.","journal-title":"Biometrics"},{"issue":"4","key":"1149_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","volume":"56","author":"YK Cheung","year":"2000","unstructured":"Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177\u201382.","journal-title":"Biometrics"},{"issue":"10","key":"1149_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17(10):1103\u201320.","journal-title":"Stat Med"},{"issue":"487","key":"1149_CR9","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1198\/jasa.2009.ap08425","volume":"104","author":"G Yin","year":"2009","unstructured":"Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. J Am Stat Assoc. 2009;104(487):954\u201368.","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"1149_CR10","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1214\/13-AOAS661","volume":"7","author":"S Liu","year":"2013","unstructured":"Liu S, Yin G, Yuan Y. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Ann Appl Stat. 2013;7(4):1837\u20132457.","journal-title":"Ann Appl Stat"},{"issue":"17","key":"1149_CR11","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/sim.4069","volume":"30","author":"EM Van Meter","year":"2011","unstructured":"Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. Stat Med. 2011;30(17):2070\u201380.","journal-title":"Stat Med"},{"issue":"3","key":"1149_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1740774512443593","volume":"9","author":"EM Van Meter","year":"2012","unstructured":"Van Meter EM, Garrett-Mayer E, Bandyopadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clin Trials. 2012;9(3):303\u201313.","journal-title":"Clin Trials"},{"issue":"3","key":"1149_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0197-2456(01)00205-7","volume":"23","author":"TM Braun","year":"2002","unstructured":"Braun TM. The bivariate continual reassessment method. Extending the CRM to phase I trials of two competing outcomes. Control Clin Trials. 2002;23(3):240\u201356.","journal-title":"Control Clin Trials"},{"issue":"15","key":"1149_CR14","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-0220","volume":"23","author":"F Yan","year":"2017","unstructured":"Yan F, Mandrekar SJ, Yuan Y. Keyboard: a novel Bayesian toxicity probability interval Design for Phase I Clinical Trials. Clin Cancer Res. 2017;23(15):3994\u20134003.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1149_CR15","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/sim.7674","volume":"37","author":"H Zhou","year":"2018","unstructured":"Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Stat Med. 2018;37(14):2208\u201322.","journal-title":"Stat Med"},{"key":"1149_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00032","volume":"3","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Lee JJ, Hilsenbeck SG. Model-assisted designs for early-phase clinical trials: simplicity meets superiority. JCO Precis Oncol. 2019;3:1\u201312.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"1149_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7(6):653\u201363.","journal-title":"Clin Trials"},{"issue":"17","key":"1149_CR18","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res. 2016;22(17):4291\u2013301.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1149_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cmpb.2007.06.006","volume":"88","author":"A Kramar","year":"2007","unstructured":"Kramar A, Hou\u00e9d\u00e9 N, Paoletti X. np1: a computer program for dose escalation strategies in phase I clinical trials. Comput Methods Prog Biomed. 2007;88(1):8\u201317.","journal-title":"Comput Methods Prog Biomed"},{"key":"#cr-split#-1149_CR20.1","doi-asserted-by":"crossref","unstructured":"Sweeting M, Mander A, Sabin T. bcrm : Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials. J Stat Softw. 2013;54","DOI":"10.18637\/jss.v054.i13"},{"key":"#cr-split#-1149_CR20.2","unstructured":"(13) [cited 2017 Jun 7]. Available from: http:\/\/www.jstatsoft.org\/v54\/i13\/."},{"issue":"13","key":"1149_CR21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/sim.4128","volume":"30","author":"A Mauguen","year":"2011","unstructured":"Mauguen A, Le Deley MC, Zohar S. Dose-finding approach for dose escalation with overdose control considering incomplete observations. Stat Med. 2011;30(13):1584\u201394.","journal-title":"Stat Med"},{"issue":"24","key":"1149_CR22","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/sim.3682","volume":"28","author":"X Paoletti","year":"2009","unstructured":"Paoletti X, Kramar A. A comparison of model choices for the continual reassessment method in phase I cancer trials. Stat Med. 2009;28(24):3012\u201328.","journal-title":"Stat Med"},{"issue":"3","key":"1149_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1740774509105076","volume":"6","author":"SM Lee","year":"2009","unstructured":"Lee SM. Ying Kuen Cheung null. Model calibration in the continual reassessment method. Clin Trials. 2009;6(3):227\u201338.","journal-title":"Clin Trials"},{"issue":"1","key":"1149_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/biostatistics\/3.1.87","volume":"3","author":"J O\u2019Quigley","year":"2002","unstructured":"O\u2019Quigley J. Continual reassessment designs with early termination. Biostatistics. 2002;3(1):87\u201399.","journal-title":"Biostatistics"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-01149-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-020-01149-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-01149-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T09:01:15Z","timestamp":1723107675000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-020-01149-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1186\/s12911-020-01149-3","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}